Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (371-380 of 740) with videos related to

Pageof 74
Sort By:
Hemasphere|March 4, 2024
Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator, particularly for R-ISS II patientsMaria Papatsirou, Christos K Kontos, Ioannis Ntanasis-Stathopoulos, et al.
Cancer|September 12, 2018
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trialMeletios A Dimopoulos, Sagar Lonial, Keith A Betts, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|January 15, 2018
Stage-II thymoma and emergency coronary artery bypass. To irradiate or not to irradiate to avoid radiation induced vascular injury? Case report and literature reviewIlias A Kouerinis, Maria Tolia, Flora Zagouri, et al.
Oxidative Medicine and Cellular Longevity|December 16, 2016
Evidence of a Redox-Dependent Regulation of Immune Responses to Exercise-Induced InflammationAlexandra Sakelliou, Ioannis G Fatouros, Ioannis Athanailidis, et al.
Biomedicines|February 25, 2022
Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning AnalysisDimitris Papadopoulos, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, et al.
Clinical and Experimental Medicine|July 20, 2021
Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccineMaria Gavriatopoulou, Evangelos Terpos, Efstathios Kastritis, et al.
International Journal of Cancer|March 30, 2011
VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2Apostolos C Ziogas, Nikos G Gavalas, Marinos Tsiatas, et al.
The Journal of Infection|May 16, 2021
Epidemiology and organ specific sequelae of post-acute COVID19: A narrative reviewEleni Korompoki, Maria Gavriatopoulou, Rachel S Hicklen, et al.
American Journal of Hematology|November 15, 2021
Kinetics of anti-SARS-CoV-2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapyEfstathios Kastritis, Evangelos Terpos, Zoi Evangelakou, et al.
Radiology|April 5, 2022
Comparison of MRI Features of Fat Fraction and ADC for Early Treatment Response Assessment in Participants with Multiple MyelomaVassilis Koutoulidis, Evangelos Terpos, Nikolaos Papanikolaou, et al.
Pageof 74

Showing results (371-380 of 740) with videos related to

Sort By:
Pageof 74
Hemasphere|March 4, 2024
Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator, particularly for R-ISS II patientsMaria Papatsirou, Christos K Kontos, Ioannis Ntanasis-Stathopoulos, et al.
Cancer|September 12, 2018
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trialMeletios A Dimopoulos, Sagar Lonial, Keith A Betts, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|January 15, 2018
Stage-II thymoma and emergency coronary artery bypass. To irradiate or not to irradiate to avoid radiation induced vascular injury? Case report and literature reviewIlias A Kouerinis, Maria Tolia, Flora Zagouri, et al.
Oxidative Medicine and Cellular Longevity|December 16, 2016
Evidence of a Redox-Dependent Regulation of Immune Responses to Exercise-Induced InflammationAlexandra Sakelliou, Ioannis G Fatouros, Ioannis Athanailidis, et al.
Biomedicines|February 25, 2022
Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning AnalysisDimitris Papadopoulos, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, et al.
Clinical and Experimental Medicine|July 20, 2021
Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccineMaria Gavriatopoulou, Evangelos Terpos, Efstathios Kastritis, et al.
International Journal of Cancer|March 30, 2011
VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2Apostolos C Ziogas, Nikos G Gavalas, Marinos Tsiatas, et al.
The Journal of Infection|May 16, 2021
Epidemiology and organ specific sequelae of post-acute COVID19: A narrative reviewEleni Korompoki, Maria Gavriatopoulou, Rachel S Hicklen, et al.
American Journal of Hematology|November 15, 2021
Kinetics of anti-SARS-CoV-2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapyEfstathios Kastritis, Evangelos Terpos, Zoi Evangelakou, et al.
Radiology|April 5, 2022
Comparison of MRI Features of Fat Fraction and ADC for Early Treatment Response Assessment in Participants with Multiple MyelomaVassilis Koutoulidis, Evangelos Terpos, Nikolaos Papanikolaou, et al.
Pageof 74